Seminars in Oncology
Volume 36, Issue 5 , Pages 439-450 , October 2009

Colorectal Cancer in Young Adults

  • Kevin Zbuk

      Affiliations

    • Juravinski Cancer Center and McMaster University, Hamilton, Ontario, Canada
    • Corresponding Author InformationAddress correspondence to Kevin Zbuk, MD, Department of Medical Oncology, Juravinksi Cancer Centre, Hamilton, Ontario, Canada L8V-5C2
    • ,
  • Emma L. Sidebotham

      Affiliations

    • Department of Surgery, Pediatric Surgical Service, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Archie Bleyer

      Affiliations

    • St. Charles Medical Center, Bend, OR
    • ,
  • Michael P. La Quaglia

      Affiliations

    • Department of Surgery, Pediatric Surgical Service, Memorial Sloan-Kettering Cancer Center, New York, NY

References 

  1. O'Connell JB, Maggard MA, Livingston EH, Yo CK. Colorectal cancer in the young. Am J Surg. 2004;187:343–348
  2. O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. Am Surg. 2003;69:866–872
  3. O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Do young colon cancer patients have worse outcomes?. World J Surg. 2004;28:558–562
  4. Griffin PM, Liff JM, Greenberg RS, Clark WS. Adenocarcinomas of the colon and rectum in persons under 40 years old (A population-based study). Gastroenterology. 1991;100:1033–1040
  5. Durno CA, Gallinger S. Genetic predisposition to colorectal cancer: new pieces in the pediatric puzzle. J Pediatr Gastroenterol Nutr. 2006;43:5–15
  6. Kastrinos F, Stoffel EM, Balmana J, Steyerberg EW, Mercado R, Syngal S. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States. Cancer Epidemiol Biomarkers Prev. 2008;17:2044–2051
  7. Goecke T, Schulmann K, Engel C, Holinski-Feder E, Pagenstecher C, Schackert HK, et al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J Clin Oncol. 2006;24:4285–4292
  8. Evans DG, Walsh S, Hill J, McMahon RT. Strategies for identifying hereditary nonpolyposis colon cancer. Semin Oncol. 2007;34:411–417
  9. Watson PLH. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer. 1993;71:677–685
  10. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34:424–425
  11. Durno C, Aronson M, Bapat B, Cohen Z, Gallinger S. Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma. Gut. 2005;54:1146–1150
  12. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–268
  13. Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R, Porteous ME, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006;354:2751–2763
  14. Stigliano V, Assisi D, Cosimelli M, Palmirotta R, Giannarelli D, Mottolese M, et al. Survival of hereditary non-polyposis colorectal cancer patients compared with sporadic colorectal cancer patients. J Exp Clin Cancer Res. 2008;27:39
  15. Dionigi G, Bianchi V, Villa F, Rovera F, Boni L, Annoni M, et al. Differences between familial and sporadic forms of colorectal cancer with DNA microsatellite instability. Surg Oncol. 2007;16(Suppl 1):S37–S42
  16. Al-Sukhni W, Aronson M, Gallinger S. Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome. Surg Clin North Am. 2008;88:819–844
  17. Giardiello FM, Petersen GM, Brensinger JD, Luce MC, Cayouette MC, Bacon J, et al. Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. Gut. 1996;39:867–869
  18. LeSher A, Castronuovo JJ, Fillippone AL. Hepatoblastoma in a patient with familial polyposis coli. Surgery. 1989;105:668–670
  19. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. Gastroenterology. 2003;124:544–560
  20. Leddin D, Hunt R, Champion M, Cockeram A, Flook N, Gould M, et al. Canadian Association of Gastroenterology and the Canadian Digestive Health Foundation: guidelines on colon cancer screening. Can J Gastroenterol. 2004;18:93–99
  21. Vogelstein B. Genetic testings for cancer: the surgeon's critical role (Familial colon cancer). J Am Coll Surg. 1999;188:74–79
  22. Caspari R, Friedl W, Mandl M, Moslein G, Kadmon M, Knapp M, et al. Familial adenomatous polyposis: mutation at codon 1309 and early onset of colon cancer. Lancet. 1994;343:629–632
  23. Caspari R, Olschwang S, Friedl W, Mandl M, Boisson C, Boker T, et al. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet. 1995;4:337–340
  24. Couture J, Mitri A, Lagace R, Smits R, Berk T, Bouchard HL, et al. A germline mutation at the extreme 3′ end of the APC gene results in a severe desmoid phenotype and is associated with overexpression of beta-catenin in the desmoid tumor. Clin Genet. 2000;57:205–212
  25. Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat Genet. 2002;30:227–232
  26. Enholm S, Hienonen T, Suomalainen A, Lipton L, Tomlinson I, Karja V, et al. Proportion and phenotype of MYH-associated colorectal neoplasia in a population-based series of Finnish colorectal cancer patients. Am J Pathol. 2003;163:827–832
  27. Zbuk KM, Eng C. Hamartomatous polyposis syndromes. Nat Clin Pract Gastroenterol Hepatol. 2007;4:492–502
  28. Hill DA, Furman WL, Billups CA, Riedley SE, Cain AM, Rao BN, et al. Colorectal carcinoma in childhood and adolescence: a clinicopathologic review. J Clin Oncol. 2007;25:5808–5814
  29. American Academy of Pediatrics Section on Hematology/Oncology Children's Oncology Group. Long-term follow-up care for pediatric cancer survivors. Pediatrics. 2009;123:906–915
  30. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther. 2006;23:1097–1104
  31. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–535
  32. LaQuaglia MP, Heller G, Filippa DA, Karasakalides A, Vlamis V, Wollner N, et al. Prognostic factors and outcome in patients 21 years and under with colorectal carcinoma. J Pediatr Surg. 1992;27:1085–1089
  33. Kravarusic D, Feigin E, Dlugy E, Steinberg R, Baazov A, Erez I, et al. Colorectal carcinoma in childhood: a retrospective multicenter study. J Pediatr Gastroenterol Nutr. 2007;44:209–211
  34. Sivit CJ. Contemporary imaging in abdominal emergencies. Pediatr Radiol. 2008;38(Suppl 4):S675–S678
  35. Stevenson GW. Radiology and endoscopy in the pretreatment diagnostic management of colorectal cancer. Cancer. 1993;71(Suppl):4198–4206
  36. Galia M, Midiri M, Carcione A, Cusma S, Bartolotta TV, Angileri T, et al. Usefulness of CT colonography in the preoperative evaluation of patients with distal occlusive colorectal carcinoma. Radiol Med. 2001;101:235–242
  37. MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007;243:132–139
  38. Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW, Williams GT. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg. 2003;90:355–364
  39. Vikram R, Iyer RB. PET/CT imaging in the diagnosis, staging, and follow-up of colorectal cancer. Cancer Imaging. 2008;8(Suppl A):S46–S51
  40. Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, et al. Colon cancer clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2005;3:468–491
  41. In:  Greene FL,  Page DL,  Fleming ID,  Fritz A,  Balch CM,  Haller DG, et al. editor. AJCC cancer staging manual. 6th ed.. Berlin: Springer Verlag; 2002;
  42. Astler VB, Coller FA. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg. 1954;139:846–852
  43. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008;8:288–298
  44. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer. 2003;3:695–701
  45. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–618
  46. Quah HM, Joseph R, Schrag D, Shia J, Guillem JG, Paty PB, et al. Young age influences treatment but not outcome of colon cancer. Ann Surg Oncol. 2007;14:2759–2765
  47. Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–3419
  48. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004;22:3395–3407
  49. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Quasar Collaborative Group Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–2029
  50. Ota D, Nelson H. The surgeon and adjuvant therapy for stage II colon cancer. Ann Surg Oncol. 2007;14:272–273
  51. Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol. 2003;21:2896–2903
  52. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–2351
  53. Harmon KE, Ryan JA, Biehl TR, Lee FT. Benefits and safety of hepatic resection for colorectal metastases. Am J Surg. 1999;177:402–404
  54. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–237
  55. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345
  56. Freyer G, Rougier P, Bugat R, Droz JP, Marty M, Bleiberg H, et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure (CPT-11 F205, F220, F221 and V222 study groups). Br J Cancer. 2000;83:431–437
  57. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis (Colorectal Cancer Collaborative Group). BMJ. 2000;321:531–535
  58. Peeters M, Balfour J, Arnold D. Review article: panitumumab—a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. Aliment Pharmacol Ther. 2008;28:269–281
  59. Yan L, Hsu K, Beckman RA. Antibody-based therapy for solid tumors. Cancer J. 2008;14:178–183
  60. Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, et al. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer. 2007;97:1469–1474
  61. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040–2048
  62. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  63. Seegenschmiedt MH, Martus P, Goldmann AR, Wolfel R, Keilholz L, Sauer R. Preoperative versus postoperative radiotherapy for prevention of heterotopic ossification (HO): first results of a randomized trial in high-risk patients. Int J Radiat Oncol Biol Phys. 1994;30:63–73
  64. Engstrom P. Update: NCCN colon cancer clinical practice guidelines. J Natl Compr Cancer Netw. 2005;3(Suppl 1):S25–S28
  65. Kumar A, Ansari M, Shukla D, Tripathi AK, Shyam R. Augmentation gastroplasty using a segment of transverse colon for corrosive gastric stricture. Int J Colorectal Dis. 2006;21:470–472
  66. Tohme C, Labaki M, Hajj G, Abboud B, Noun R, Sarkis R. Colorectal cancer in young patients: presentation, clinicopathological characteristics and outcome. J Med Liban. 2008;56:208–214
  67. O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Ko CY. Are survival rates different for young and older patients with rectal cancer?. Dis Colon Rectum. 2004;47:2064–2069
  68. Datta RV, LaQuaglia MP, Paty PB. Genetic and phenotypic correlates of colorectal cancer in young patients. N Engl J Med. 2000;342:137–138
  69. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69–77
  70. Muller CI, Schulmann K, Reinacher-Schick A, Andre N, Arnold D, Tannapfel A, et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy (A report of the AIO Colorectal Study Group). Int J Colorectal Dis. 2008;23:1033–1039
  71. des Guetz G, Mariani P, Cucherousset J, Benamoun M, Lagorce C, Sastre X, et al. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res. 2007;27:2715–2719
  72. Fallik D, Borrini F, Boige V, Viguier J, Jacob S, Miquel C, et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 2003;63:5738–5744
  73. Spanos CP, Mamopoulos A, Tsapas A, Syrakos T, Kiskinis D. Female fertility and colorectal cancer. Int J Colorectal Dis. 2008;23:735–743
  74. Marhhom E, Cohen I. Fertility preservation options for women with malignancies. Obstet Gynecol Surv. 2007;62:58–72
  75. Strong M, Peche W, Scaife C. Incidence of fertility counseling of women of child-bearing age before treatment for colorectal cancer. Am J Surg. 2007;194:765–767
  76. Olsen KO, Joelsson M, Laurberg S, Oresland T. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg. 1999;86:493–495
  77. Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod. 2003;18:117–121
  78. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917–2931
  79. Saif MW. Management of colorectal cancer in pregnancy: a multimodality approach. Clin Colorectal Cancer. 2005;5:247–256
  80. Cappell MS. Colon cancer during pregnancy. Gastroenterol Clin North Am. 2003;32:341–383
  81. Gensheimer M, Jones CA, Graves CR, Merchant NB, Lockhart AC. Administration of oxaliplatin to a pregnant woman with rectal cancer. Cancer Chemother Pharmacol. 2009;63:371–373
  82. Kanate AS, Auber ML, Higa GM. Priorities and uncertainties of administering chemotherapy in a pregnant woman with newly diagnosed colorectal cancer. J Oncol Pharm Pract. 2009;15:5–8

 Supported in part by the Aflac Foundation

PII: S0093-7754(09)00143-2

doi: 10.1053/j.seminoncol.2009.07.008

Seminars in Oncology
Volume 36, Issue 5 , Pages 439-450 , October 2009

Article Tools

* Image Usage & Resolution